Skip to main content
Circio Holding ASA logo

Circio Holding ASA — Investor Relations & Filings

Ticker · CRNA ISIN · NO0013033795 LEI · 5967007LIEEXZXFYNS31 OL Professional, scientific and technical activities
Open in API
Filings indexed 175 across all filing types
Latest filing 2026-05-29 Director's Dealing
Country NO Norway
Listing OL CRNA

About Circio Holding ASA

https://www.targovax.com/en/

Circio Holding ASA is a clinical-stage company developing novel medicines based on circular RNA (circRNA) and immunotherapy. The company's core focus is its proprietary circVec platform, a circular RNA expression system designed to enhance the efficacy and durability of gene and cell therapies. Circio's development pipeline is directed towards immuno-oncology, targeting difficult-to-treat solid tumors, and the application of its circRNA technology to address genetic diseases.

Recent filings

Filing Released Lang Actions
Circio Holding ASA Exercise of Warrants by primary insiders - Attachment: Notification Of Trade By Primary Insiders Exercised Warrants.pdf
Director's Dealing Classification · 95% confidence The document is a notification of transactions by primary insiders and their close associates, detailing insider trades (exercise of warrants, volumes, prices, dates, places) for company directors and their associates. This clearly corresponds to the Director’s Dealing category.
2026-05-29 English
Circio Holding ASA Exercise of Warrants by primary insiders
Director's Dealing Classification · 92% confidence The document details the exercise of warrants by primary insiders (board member and CEO), reporting their personal share transactions. This falls under insider trading disclosures by company directors/executives. Therefore, it is a Director’s Dealing filing.
2026-05-29 English
Circio hosts live webcast today 28 May 2026 at 10:00 am CEST - Attachment: 260528 Circio Webcast.pdf
Investor Presentation Classification · 90% confidence The document is a slide deck titled with company branding, disclaimers, slide numbers, and contains investor‐oriented content such as business updates, M&A context, warrant program, and use of proceeds. It is clearly a corporate presentation for investors (not a regulatory filing, earnings release, call transcript, or annual report). Therefore it is an Investor Presentation.
2026-05-28 English
Circio hosts live webcast today 28 May 2026 at 10:00 am CEST
Report Publication Announcement Classification · 92% confidence The document is a short press release (3,393 characters) announcing a live webcast and advising that presentation materials are attached. It does not contain substantive financial or R&D data itself, nor the full investor presentation slides; rather it directs readers to an attached presentation. Under the “menu vs. meal” rule, it is an announcement of publication of materials rather than the materials themselves. Therefore, it is classified as a Report Publication Announcement (RPA).
2026-05-28 English
Circio and AaviGen jointly announce research collaboration to advance novel gene therapies for heart diseases
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing a research collaboration between Circio and AaviGen. It contains no financial statements, no details of dividends or share transactions, no management or board changes, no proxy statements, and no regulatory forms. It does not present an actual annual or interim report, nor is it an announcement of voting results or a financing activity. It simply communicates corporate news about a joint research project, which falls under general regulatory announcements. Therefore, it should be classified as a Regulatory Filing (RNS), the fallback category for miscellaneous corporate disclosures.
2026-05-27 English
Announcement of the terms of the underwriting and the Unused Warrants Option Agreement in connection with the Warrant Program
Share Issue/Capital Change Classification · 85% confidence The document is a stock exchange announcement detailing the terms of a warrant program, including new share subscription rights, underwriting agreements, private placements deviating from shareholders’ preferential rights, and capital raising proceeds. It is an announcement of a new share issue/capital change rather than a financial report, management commentary, or regulatory filing report. Therefore, it falls under Share Issue/Capital Change (SHA).
2026-05-26 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.